Skip to content

ADLs at the End of Acute Treatment for Childhood Leukemia and Non-Hodgkin Lymphoma

Activities of Daily Living at the End of Acute Treatment for Acute Leukemia or Non-Hodgkin Lymphona During Childhood and Adolescence

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05235633
Enrollment
20
Registered
2022-02-11
Start date
2022-04-19
Completion date
2027-12-31
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Cancer

Keywords

Activities of daily living, Leukemia, Non-Hodgkin Lymphoma, Physical activity, Motor performance

Brief summary

Reduced activity levels and reduced muscular strength could severely impair the activities of daily living (ADLs) in pediatric leukemia and Non-Hodgkin lymphoma patients. Increased muscle strength is associated with improved accomplishment of ADLs and consequently greatest possible normality, autonomy and mobility. This associated investigation to the study with the ClinicalTrials.gov Identifier NCT03934060 aims at collecting data in a comparison cohort with respect to ADLs in children and adolescents who did not receive a standardized strenght training intervention during the whole course of treatment.

Interventions

DIAGNOSTIC_TESTAssessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment

Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.

Sponsors

Technical University of Munich
Lead SponsorOTHER
Ludwig-Maximilians - University of Munich
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children and adolescents aged 4-18 years * At the end of acute treament for leukemia or non-Hodgkin lymphoma * Diagnosed and/or treated at the Dr. von Hauner Children's Hospital, University of Munich * Informed consent as documented by signature

Exclusion criteria

* Medical contraindication to perform this unique test battery (e.g., acute bleeding risk, pain, nausea, acute orthopedic impairments) * Inability to follow study procedures (e.g., language problems, mental retardation)

Design outcomes

Primary

MeasureTime frameDescription
Score of the Activities Scale for Kids - performance versionDuring the procedureThe ASK - Activities Scale for Kids performance version by NL Young assesses an overall summary score (0-100) of self-reported activities of daily living in children and adolescents. The scale monitors changes associated with therapeutic interventions and the current status of accomplishment of activities of daily living. Higher values represent a better outcome. The ASK contains 30 items in 7 sub-domains (personal care, dressing, other skills, locomotion, play, standing skills and transfer).

Secondary

MeasureTime frameDescription
Motor PerformanceDuring the procedureMotor performance is assessed by the MOON-test (Motor performance test in Pediatiric Oncology), a tool to examine motor performance abilities in children and adolescents during and after cancer treatment. There's no summary score; reference values of healthy children enable comparison of the tested children.
Performance in a Parkour in Activities of Daily LivingDuring the procedureA standardized parkour with tasks imitating activities of daily living is used to objectively verify the ASK score. Points from 0-4 are counted for each task depending on quality of movement (0 = task can not be completed, 1 = task can be completed with help, 2 = task can be completed with several attempts, 3 = task can be completed with only little effort, 4 = task can be completed without any problems or effort). There are no reference values for the parkour, but intra-individual changes are analyzed.

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORSabine Kesting

Kinderklinik München Schwabing TUM School of Medicine, Department of Pediatrics and Children's Cancer Research Center, Technical University of Munich

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026